HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Supporting Denigrating Ad Claims: From Actors’ Facial Expressions To Fact-Based Humor

Executive Summary

Like other comparative claims, say attorneys at the National Advertising Division’s annual conference, advertising that denigrates a competing brand must be substantiated. Advertising detailed previously in HBW Insight that compared nutritional products’ formulations and skin moisturizers’ effectiveness were noted as examples of denigrating claims. 

You may also be interested in...



Kind’s Specific Ingredient Claims Remain Airborne After General Comparison To Clif Bar Line Grounded

National Advertising Division says a TV commercial Kind previously aired claiming “75% less sugar than the leading Clif bar” made an unfair “line claim.” But Kind says "ultimately this issue is moot" as it stopped using the "commercial (which takes place on an airplane) many months ago in light of the COVID-19 pandemic.”

NAD Shoots Down Dove Ad Claims In Dial Dispute

Ad watchdog group NAD calls for Unilever’s Dove brand to back off from ad claims against competitor Dial, finding them unverified and disparaging. NAD also objects to “proven best care” claims that lack a foundation of direct testing.

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS150538

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel